Rossari Biotech

Why is Rossari Biotech Ltd falling/rising?

As of 24-Jun, Rossari Biotech Ltd's stock price is rising to Rs 537.50, reflecting a slight upward change. Despite today's increase, the stock has faced long-term challenges, including a year-to-date decline of 7.31%, while the company's profits have grown by 9.4%.

As of 24-Jun, Rossari Biotech Ltd's stock price is rising, currently at Rs 537.50, reflecting a change of 1.35 (0.25%) upward. This increase can be attributed to a trend reversal, as the stock has gained after two consecutive days of decline. Additionally, it has outperformed its sector by 0.5% today. <BR><BR>Despite the positive movement today, the stock has faced significant challenges over the longer term, including a year-to-date decline of 7.31% and a 19.49% drop over the past year. However, the company's profits have increased by 9.4% during this time, indicating that while the stock price has fallen, the underlying business performance has shown some resilience. <BR><BR>Investor participation has decreased, with delivery volume falling by 60.95% against the 5-day average, which may indicate a lack of confidence among retail investors. The stock is trading at a discount compared to its peers' average historical valuations, which could attract institutional investors, as evidenced by a high institutional holding of 20.38%. <BR><BR>Overall, while the stock is experiencing a rise today, it remains under pressure from its historical performance and declining investor participation.

Which are the latest news on Rossari Biotech?

Should I buy, sell or hold Rossari Biotech Ltd?

What does Rossari Biotech do?

Rossari Biotech Ltd is a small-cap company in the specialty chemicals industry, founded in 2003 and converted to a corporate entity in 2009. As of March 2026, it reported net sales of ₹685 Cr and a net profit of ₹46 Cr, with a market cap of ₹2,845 Cr.

Overview:<BR>Rossari Biotech Ltd operates in the specialty chemicals industry and is categorized as a small-cap company.<BR><BR>History:<BR>Rossari Biotech Limited was founded in 2003 as a partnership firm named Rossari Labtech and was established by Mr. Edward Walter Menezes and Mr. Sunil Srinivasan Chari. The company was renamed to Rossari Biotech Limited and converted into a corporate entity in 2009. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 685 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 46 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 2,845 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 19.00<BR>- Industry P/E: 42<BR>- Dividend Yield: 0.00%<BR>- Debt-Equity: 0.23<BR>- Return on Equity: 11.19%<BR>- Price to Book: 2.13<BR><BR>Contact Details:<BR>Details: No Company Details Available<BR>Registrar Address: Not available.

How big is Rossari Biotech?

As of 10th June, Rossari Biotech Ltd has a market capitalization of 2,845.00 Cr, with net sales of 2,396.37 Cr and a net profit of 149.22 Cr over the latest four quarters.

As of 10th June, Rossari Biotech Ltd has a market capitalization of 2,845.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Rossari Biotech reported net sales of 2,396.37 Cr and a net profit of 149.22 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with shareholder's funds amounting to 1,185.45 Cr and total assets of 1,885.67 Cr.

Who are in the management team of Rossari Biotech?

The management team of Rossari Biotech includes Sunil Chari (Managing Director), Edward Menezes (Chairman & Executive Director), and several independent directors, along with Parul Gupta (Company Secretary) and additional directors. They are responsible for the company's strategic direction and regulatory compliance.

The management team of Rossari Biotech includes the following key individuals:<BR><BR>1. **Sunil Chari** - Managing Director<BR>2. **Edward Menezes** - Chairman & Executive Director<BR>3. **Goutam Bhattacharya** - Non-Executive & Independent Director<BR>4. **Aseem Dhru** - Non-Executive & Independent Director<BR>5. **Sharabh Pachory** - Non-Executive & Independent Director<BR>6. **Parul Gupta** - Company Secretary & Compliance Officer<BR>7. **Aparna Narendra Sharma** - Additional Independent Director<BR>8. **Esha Padmanabhan Achan** - Additional Director<BR><BR>This team plays a crucial role in guiding the company's strategic direction and ensuring compliance with regulatory standards.

Who are the peers of the Rossari Biotech?

Peers of Rossari Biotech include Laxmi Organic, Vishnu Chemicals, Styrenix Perfor., Foseco India, Yasho Industries, Jubilant Agri, NOCIL, Tatva Chintan, and DDev Plastiks. Rossari Biotech has good management risk and average growth, with a 1-year return of -27.16%.

Peers: The peers of Rossari Biotech are Laxmi Organic, Vishnu Chemicals, Styrenix Perfor., Foseco India, Yasho Industries, Jubilant Agri, NOCIL, Tatva Chintan, DDev Plastiks.<BR><BR>Quality Snapshot: Excellent management risk is observed at Vishnu Chemicals, Styrenix Perfor., Foseco India, and Jubilant Agri, while Good management risk is found at Rossari Biotech. Average management risk is present at Laxmi Organic, Yasho Industries, NOCIL, Tatva Chintan, DDev Plastiks, and the rest. Below Average management risk is noted at Camlin Fine. Growth is Excellent at Jubilant Agri, Good at Vishnu Chemicals and DDev Plastiks, while Average growth is seen at Rossari Biotech. Below Average growth is reported for Laxmi Organic, Styrenix Perfor., Yasho Industries, NOCIL, Tatva Chintan, and the rest. Capital Structure is Excellent for Laxmi Organic, Styrenix Perfor., Foseco India, Jubilant Agri, NOCIL, Tatva Chintan, DDev Plastiks, while Average is found at Vishnu Chemicals, and Below Average at Yasho Industries.<BR><BR>Return Snapshot: Yasho Industries has the highest 1-year return at 25.06%, while Styrenix Perfor. has the lowest at -37.31%. Rossari Biotech's 1-year return is -27.16%, which is better than Styrenix Perfor. but worse than Yasho Industries. Additionally, the six-month return is negative for Laxmi Organic, Foseco India, Rossari Biotech, NOCIL, Tatva Chintan, DDev Plastiks, and Camlin Fine.

Are Rossari Biotech Ltd latest results good or bad?

Rossari Biotech Ltd's latest results show strong sales and a significant profit increase, but concerns arise from declining operating margins and reliance on exceptional income, indicating potential sustainability issues. Investors should approach with caution due to these mixed signals.

The latest results for Rossari Biotech Ltd present a mixed picture. On the positive side, the company reported a consolidated net profit of ₹45.97 crore for Q4 FY26, which is a significant increase of 40.28% quarter-on-quarter and 33.48% year-on-year. Additionally, net sales rose to ₹684.86 crore, reflecting a growth of 17.74% QoQ and 18.17% YoY. These figures indicate strong revenue growth and improved profitability in the short term.<BR><BR>However, there are notable concerns beneath the surface. The operating margin, excluding other income, decreased to 11.28%, down from 11.84% in the previous quarter and 11.99% a year ago. This margin compression raises questions about the company's operational efficiency. Furthermore, the substantial profit increase was partly driven by exceptional other income of ₹19.07 crore, which is significantly higher than typical levels seen in previous quarters. This reliance on one-time income sources could indicate potential sustainability issues regarding future earnings.<BR><BR>Additionally, Rossari Biotech has faced challenges in the market, with its stock underperforming significantly compared to the broader market and its peers in the specialty chemicals sector. The company’s return on equity stands at a modest 10.92%, which is below the peer average, suggesting inefficiencies in capital deployment.<BR><BR>In summary, while the latest results show strong sales and profit growth, the underlying operational challenges and reliance on exceptional income raise concerns about the sustainability of this performance. Investors may want to approach with caution given these mixed signals.

Is Rossari Biotech technically bullish or bearish?

As of December 2, 2025, Rossari Biotech's trend is mildly bearish, indicated by bearish MACD and moving averages, mixed RSI signals, and mildly bearish Bollinger Bands, suggesting a cautious outlook.

As of 2 December 2025, the technical trend for Rossari Biotech has changed from bearish to mildly bearish. The current stance is mildly bearish with key indicators driving this assessment being the MACD on both the weekly and monthly time frames, which remain bearish, and the daily moving averages also indicating a bearish trend. The RSI shows a bullish signal on the monthly but no signal on the weekly, suggesting mixed momentum. Bollinger Bands are mildly bearish on both weekly and monthly charts, while KST indicates a mildly bullish stance on the weekly but bearish on the monthly. Overall, the lack of definitive bullish signals and the presence of bearish indicators suggest a cautious outlook.

How has been the historical performance of Rossari Biotech?

Rossari Biotech has demonstrated consistent growth in net sales and profits, with net sales increasing from INR 600.09 crore in March 2020 to INR 2,080.29 crore in March 2025, and profit after tax rising from INR 65.47 crore to INR 135.40 crore during the same period. The company's earnings per share improved from INR 12.86 to INR 24.64, reflecting enhanced shareholder value.

Answer:<BR>The historical performance of Rossari Biotech shows a consistent growth trajectory in net sales and profits over the past several years.<BR><BR>Breakdown:<BR>Rossari Biotech's net sales have increased significantly from INR 600.09 crore in March 2020 to INR 2,080.29 crore in March 2025, reflecting a robust annual growth trend. The total operating income followed a similar pattern, rising from INR 600.09 crore in March 2020 to INR 2,080.29 crore in March 2025. The company's operating profit (PBDIT) also demonstrated a positive trend, growing from INR 108.46 crore in March 2020 to INR 269.08 crore in March 2025. Profit before tax increased from INR 88.06 crore in March 2020 to INR 184.21 crore in March 2025, while profit after tax rose from INR 65.47 crore to INR 135.40 crore during the same period. The earnings per share (EPS) improved from INR 12.86 in March 2020 to INR 24.64 in March 2025, indicating enhanced shareholder value. On the balance sheet, total assets grew from INR 471.46 crore in March 2020 to INR 1,885.67 crore in March 2025, with total liabilities increasing from INR 471.46 crore to INR 1,885.67 crore as well. The cash flow from operating activities saw a notable rise from INR 56 crore in March 2020 to INR 137 crore in March 2025, while the net cash inflow turned positive at INR 19 crore in March 2025, compared to a negative outflow in previous years. Overall, Rossari Biotech has shown strong financial performance and growth across multiple metrics over the years.

When is the next results date for Rossari Biotech?

Rossari Biotech will announce its results on 15 October 2025.

Rossari Biotech will declare its results on 15 October 2025.

Who are the top shareholders of the Rossari Biotech?

The top shareholders of Rossari Biotech include promoter Edward Menezes with 29.11%, mutual funds holding 13.42%, foreign institutional investors at 3.48%, and individual investors owning 9.44%. The largest public shareholder is Uti-flexi Cap Fund with 6.04%.

The top shareholders of Rossari Biotech include the promoters, who hold the majority of the shares. Edward Menezes is the promoter with the highest holding at 29.11%. Additionally, mutual funds collectively hold 13.42% of the shares across 8 schemes, while foreign institutional investors (FIIs) hold 3.48% through 52 different entities. The highest public shareholder is Uti-flexi Cap Fund, which holds 6.04%. Individual investors collectively own 9.44% of the company.

Is Rossari Biotech overvalued or undervalued?

As of May 21, 2025, Rossari Biotech is considered very attractive and undervalued, with a PE ratio of 27.86, an EV to EBITDA of 14.73, and a ROCE of 15.36%, despite a year-to-date return of -12.35% compared to the Sensex's 5.58%.

As of 21 May 2025, the valuation grade for Rossari Biotech has moved from attractive to very attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued. Key ratios include a PE ratio of 27.86, an EV to EBITDA of 14.73, and a ROCE of 15.36%. <BR><BR>In comparison to its peers, Rossari Biotech's PE ratio is similar to that of its closest competitor, which also shows a PE of approximately 27.86, while the industry average EV to EBITDA is lower, suggesting that Rossari may have a competitive edge in profitability. Despite recent underperformance relative to the Sensex, with a year-to-date return of -12.35% compared to the Sensex's 5.58%, the company's strong fundamentals and attractive valuation metrics support the conclusion that it is undervalued in the current market.

Has Rossari Biotech declared dividend?

Yes, Rossari Biotech Ltd has declared a 25% dividend, amounting to ₹0.5 per share, with an ex-date of August 16, 2024. However, the company's total returns over various periods have been largely negative, particularly in the longer term.

Rossari Biotech Ltd has declared a 25% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 25%<BR>- Amount per share: 0.5<BR>- Ex-date: 16 Aug 24<BR><BR>Dividend Yield: 0.07%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -16.15%, with no dividend return, resulting in a total return of -16.15%.<BR><BR>Over the past year, the price return was 1.18%, with a dividend return of 0.07%, leading to a total return of 1.25%.<BR><BR>In the 2-year period, the price return was -14.66%, with a dividend return of 0.06%, resulting in a total return of -14.6%.<BR><BR>For the 3-year period, the price return was -22.58%, with a dividend return of 0.17%, leading to a total return of -22.41%.<BR><BR>In the 4-year period, the price return was -45.59%, with a dividend return of 0.16%, resulting in a total return of -45.43%.<BR><BR>Over the last 5 years, there was no price return and no dividend return, resulting in a total return of 0.0%.<BR><BR>Overall, while Rossari Biotech has declared a dividend, the total returns over various periods indicate a challenging performance, particularly in longer time frames, with significant negative price returns.